C-TYROCapacity Bio
mitophagy, mitochondrial modulators, small molecules
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-TYRO
C-TYROC-TYROmitophagy, mitochondrial modulators, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Capacity Bio mitophagy, mitochondrial modulators, small molecules
Capacity Bio is a mitochondria-focused biotechnology company developing novel mitophagy modulators. Its proprietary approach uses small molecules, peptides, and nanoparticles to enhance identification of dysfunctional mitochondria, activate mitophagy pathways, and promote clearance by autophagosomes and lysosomes. The company is advancing a first-in-class mitophagy agonist and preclinical programs focused on new mitochondrial modulators.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Capacity Bio — Early mechanism · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic